Christi Shaw, JPM19 (Credit: Jeff Rumans)
#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval
Just less than a year ago, Gilead’s Kite won a landmark okay for its second CAR-T therapy, with data that former head of global …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
